Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Chronic Myeloid Leukemia Clinical Trials

A listing of Chronic Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (125) clinical trials

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

OBJECTIVES: Primary - Determine the one- and two-year survival of patients with hematologic malignancies treated with a nonmyeloablative conditioning regimen comprising fludarabine, cyclophosphamide, and total-body irradiation followed by umbilical cord blood transplantation and post-transplant immunosuppression comprising sirolimus and mycophenolate mofetil. Secondary - Determine the six-month nonrelapse mortality of patients treated ...

Phase

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

OBJECTIVES: Primary - Determine the 1-year survival of patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine, cyclophosphamide, and fractionated total-body irradiation. Secondary - Determine the incidence of transplant-related mortality at 6 months after UCBT. - Evaluate the pattern of chimerism ...

Phase

Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

Patients with CML not achieving or losing a major cytogenetic response on whatever palliative treatment for CML, are at high risk to progress to accelerated phase and blast crisis. A new promising treatment with Imatinib (Glivec®), a tyrosine-kinase inhibitor, has been introduced recently. High rates of hematologic and cytogenetic responses ...

Phase

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

This is a non-randomized, phase II protocol to evaluate engraftment of cord blood after treatment with myeloablative conditioning of fludarabine, total body irradiation and cyclophosphamide. All patients will receive tacrolimus and mycophenolate mofetil as prophylaxis for graft-vs-host disease. Conditioning Regimen: - Days -10 to -7: Fludarabine 30mg/m2/day IV - Days ...

Phase

Analyses of Human Samples Collected in Clinical Trials

Various human samples (e.g., serum, plasma, whole blood, erythrocytes, urine, feces, bile, and/or saliva) will be collected from cancer patients enrolled on approved clinical trials, in accordance with the local protocol. These trials are being conducted at outside institutions, in collaboration with the National Cancer Institute (NCI) and the samples ...

Phase N/A

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

OBJECTIVES: Primary - Determine the incidence of engraftment, defined as achieving donor-derived neutrophil count > 500/mm³ by day 42, in infants with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes treated with a non-irradiation containing myeloablative conditioning regimen comprising busulfan, fludarabine, and melphalan followed by double umbilical cord ...

Phase

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

To participate in this study, the subject will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins in the neck or chest). Also before treatment can begin, we will test the subject's blood for viruses which ...

Phase

Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases

OBJECTIVES: Primary - Establish the feasibility of delayed infusion of ex vivo anergized donor peripheral blood mononuclear cells (PBMC) after CD34-selected megadose haploidentical hematopoietic stem cell transplantation (HSCT) in patients with hematopoietic cancers or other diseases. - Determine the feasibility of collecting parental allogeneic stimulator cells to induce anergy to ...

Phase

Cyclophosphamide Fludarabine Total-Body Irradiation and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: Primary - Determine, preliminarily, the efficacy of double-unit umbilical cord blood (UCB) transplantation (UCBT) in patients with hematologic malignancy. Secondary - Determine the incidence and rate of donor-derived neutrophil and platelet recovery in these patients. - Determine the contribution of each unit of UCB to initial and sustained engraftment ...

Phase

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: - Determine the overall survival rate at day 200 in patients with hematologic cancers or other diseases who undergo allogeneic peripheral blood stem cell transplantation using the CliniMACS® CD34 Reagent System for T-cell depletion followed by delayed T-cell add-back. - Determine the safety of this regimen, in terms of ...

Phase